Gradient Investments LLC Purchases 149 Shares of Celgene Corporation (NASDAQ:CELG)

Gradient Investments LLC boosted its stake in Celgene Corporation (NASDAQ:CELG) by 5.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,750 shares of the biopharmaceutical company’s stock after buying an additional 149 shares during the period. Gradient Investments LLC’s holdings in Celgene Corporation were worth $357,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CELG. Swiss National Bank boosted its stake in Celgene Corporation by 27.2% in the first quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after buying an additional 588,000 shares during the last quarter. Edge Wealth Management LLC raised its position in Celgene Corporation by 10.5% in the first quarter. Edge Wealth Management LLC now owns 15,920 shares of the biopharmaceutical company’s stock worth $1,979,000 after buying an additional 1,518 shares during the period. Boston Partners raised its position in Celgene Corporation by 0.3% in the first quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock worth $24,620,000 after buying an additional 541 shares during the period. Chicago Equity Partners LLC raised its position in Celgene Corporation by 148.8% in the first quarter. Chicago Equity Partners LLC now owns 86,480 shares of the biopharmaceutical company’s stock worth $10,761,000 after buying an additional 51,715 shares during the period. Finally, Catawba Capital Management VA raised its position in Celgene Corporation by 12.0% in the first quarter. Catawba Capital Management VA now owns 2,425 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 260 shares during the period. Institutional investors own 78.34% of the company’s stock.

Celgene Corporation (CELG) opened at 127.65 on Friday. The stock has a market cap of $99.87 billion, a P/E ratio of 39.53 and a beta of 1.89. The company’s 50 day moving average is $133.74 and its 200 day moving average is $124.92. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the firm posted $1.44 EPS. The company’s quarterly revenue was up 18.7% on a year-over-year basis. Equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/08/19/celgene-corporation-nasdaqcelg-shares-bought-by-gradient-investments-llc-updated.html.

Several analysts have recently commented on the stock. Cantor Fitzgerald set a $159.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, April 27th. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 price target (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. BMO Capital Markets reaffirmed an “outperform” rating and set a $160.00 price target (up previously from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded shares of Celgene Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $147.00.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the sale, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the transaction, the insider now owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. Insiders have sold 253,761 shares of company stock valued at $33,792,445 in the last three months. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit